Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0042963 (
vomiting
)
31,883
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Neuropharmacological properties of penfluridol (
TLP
-607) were investigated in experimental animals and were compared with those of haloperidol and chlorpromazine. Locomotor activity of mice significantly decreased at doses of 16-32 mg/kg p.o. Like haloperidol and chlorpromazine,
TLP
-607 (4-16 mg/kg p.o.) demonstrated catalepsy lasting for 48-72 hr in rats.
TLP
-607 strongly inhibited apomorphine-induced
emesis
in dogs and the ED50 was 0.016 mg/kg p.o. This effect lasted for 192 hr when administered 0.04 mg/kg p.o.
TLP
-607 antagnonized methamphetamine-induced stereotyped behavior in rats, and the ED50 was 1.83 ng/kg p.o.
TLP
-607 also inhibited conditioned avoidance responses in rats, and the ED50's in the pole climbing and Sidman avoidance methods were 6.73 and 3.4 mg/kg p.o., respectively.
TLP
-607 neither inhibited motor coordination nor enhanced hexobarbital-induced anesthesia in mice. These results suggest that
TLP
-607 is a potent and long-acting antipsychotic drug which has less neurotoxic side-effects.
...
PMID:[Pharmacological studies of an antipschotic agent, penfluridol. (1). The central pharmacological actions]. 82 32
